These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

326 related articles for article (PubMed ID: 31330972)

  • 1. The Potential of Cannabidiol as a Treatment for Psychosis and Addiction: Who Benefits Most? A Systematic Review.
    Batalla A; Janssen H; Gangadin SS; Bossong MG
    J Clin Med; 2019 Jul; 8(7):. PubMed ID: 31330972
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A systematic review of the antipsychotic properties of cannabidiol in humans.
    Iseger TA; Bossong MG
    Schizophr Res; 2015 Mar; 162(1-3):153-61. PubMed ID: 25667194
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Potential of Cannabidiol Treatment for Cannabis Users With Recent-Onset Psychosis.
    Hahn B
    Schizophr Bull; 2018 Jan; 44(1):46-53. PubMed ID: 29083450
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cannabidiol Cigarettes as Adjunctive Treatment for Psychotic Disorders - A Randomized, Open-Label Pilot-Study.
    Köck P; Lang E; Trulley VN; Dechent F; Mercer-Chalmers-Bender K; Frei P; Huber C; Borgwardt S
    Front Psychiatry; 2021; 12():736822. PubMed ID: 34803760
    [No Abstract]   [Full Text] [Related]  

  • 5. Efficacy of Cannabidiol for Δ-9-Tetrahydrocannabinol-Induced Psychotic Symptoms, Schizophrenia, and Cannabis Use Disorders: A Narrative Review.
    Bartoli F; Riboldi I; Bachi B; Calabrese A; Moretti F; Crocamo C; Carrà G
    J Clin Med; 2021 Mar; 10(6):. PubMed ID: 33810033
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of cannabidiol on endocannabinoid, glutamatergic and GABAergic signalling markers in male offspring of a maternal immune activation (poly I:C) model relevant to schizophrenia.
    Osborne AL; Solowij N; Babic I; Lum JS; Newell KA; Huang XF; Weston-Green K
    Prog Neuropsychopharmacol Biol Psychiatry; 2019 Dec; 95():109666. PubMed ID: 31202911
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cannabidiol improves behavioural and neurochemical deficits in adult female offspring of the maternal immune activation (poly I:C) model of neurodevelopmental disorders.
    Osborne AL; Solowij N; Babic I; Lum JS; Huang XF; Newell KA; Weston-Green K
    Brain Behav Immun; 2019 Oct; 81():574-587. PubMed ID: 31326506
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The yin and yang of cannabis-induced psychosis: the actions of Δ(9)-tetrahydrocannabinol and cannabidiol in rodent models of schizophrenia.
    Arnold JC; Boucher AA; Karl T
    Curr Pharm Des; 2012; 18(32):5113-30. PubMed ID: 22716133
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cannabidiol in the context of substance use disorder treatment: A systematic review.
    Paulus V; Billieux J; Benyamina A; Karila L
    Addict Behav; 2022 Sep; 132():107360. PubMed ID: 35580370
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cannabinoids and Schizophrenia: Risks and Therapeutic Potential.
    Manseau MW; Goff DC
    Neurotherapeutics; 2015 Oct; 12(4):816-24. PubMed ID: 26311150
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A randomised controlled trial of vaporised Δ
    Solowij N; Broyd S; Greenwood LM; van Hell H; Martelozzo D; Rueb K; Todd J; Liu Z; Galettis P; Martin J; Murray R; Jones A; Michie PT; Croft R
    Eur Arch Psychiatry Clin Neurosci; 2019 Feb; 269(1):17-35. PubMed ID: 30661105
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cannabidiol, a Cannabis sativa constituent, as an antipsychotic drug.
    Zuardi AW; Crippa JA; Hallak JE; Moreira FA; Guimarães FS
    Braz J Med Biol Res; 2006 Apr; 39(4):421-9. PubMed ID: 16612464
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Impact of Cannabidiol on Human Brain Function: A Systematic Review.
    Batalla A; Bos J; Postma A; Bossong MG
    Front Pharmacol; 2020; 11():618184. PubMed ID: 33551817
    [No Abstract]   [Full Text] [Related]  

  • 14. Cannabidiol versus placebo as adjunctive treatment in early psychosis: study protocol for randomized controlled trial.
    Dixon T; Cadenhead KS
    Trials; 2023 Nov; 24(1):775. PubMed ID: 38037108
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cannabidiol as a potential treatment for psychosis.
    Schubart CD; Sommer IE; Fusar-Poli P; de Witte L; Kahn RS; Boks MP
    Eur Neuropsychopharmacol; 2014 Jan; 24(1):51-64. PubMed ID: 24309088
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Impact of THC and CBD in Schizophrenia: A Systematic Review.
    Ahmed S; Roth RM; Stanciu CN; Brunette MF
    Front Psychiatry; 2021; 12():694394. PubMed ID: 34366924
    [No Abstract]   [Full Text] [Related]  

  • 17. Differential effects of cannabis constituents on schizophrenia-related psychosis: a rationale for incorporating cannabidiol into a schizophrenia therapeutic regimen.
    Johnson K; Weldon AJ; Burmeister MA
    Front Psychiatry; 2024; 15():1386263. PubMed ID: 38716117
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical and Preclinical Evidence for Functional Interactions of Cannabidiol and Δ
    Boggs DL; Nguyen JD; Morgenson D; Taffe MA; Ranganathan M
    Neuropsychopharmacology; 2018 Jan; 43(1):142-154. PubMed ID: 28875990
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Medical use of cannabis. Cannabidiol: a new light for schizophrenia?
    Deiana S
    Drug Test Anal; 2013 Jan; 5(1):46-51. PubMed ID: 23109356
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A systematic review of the effect of cannabidiol on cognitive function: Relevance to schizophrenia.
    Osborne AL; Solowij N; Weston-Green K
    Neurosci Biobehav Rev; 2017 Jan; 72():310-324. PubMed ID: 27884751
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.